NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

Jack, bottom-line, management is incompetent period. No waffle there. The science is promising, mainly for MGMT methylated. This is about 40% of the patient population in this trial. I don't know whether mesenchymal is part of the MGMT methylated population and if it is to what extent. Both seem to work with different pathways. Mesenchymal involves NF(nuclear factor). Mesenchymal presents a less suppressive micro-tumour environment. Thus more immunogenic. MGMT methylated promoter implies less MGMT expression thus disabling the cellular repair mechanism. So you may have a trial population of maybe 45% susceptible to DC VAX and the rest not so much to any significant effect. From my calculations I think the mOS delta is about 7 to 8 months. Overall, perhaps 4 to 5 months delta in mOS. We don't know about PFS but it appears there is trouble there with some analysis still to come. The long tail will be coming from the roughly 45% population. I think it will be approved and spring refresh hopefully has better numbers. JMHO.